Drug intelligence / Profile preview

RQ-2026

Development stage: Preclinical
Lead developer: RNAcure
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Cell Therapies
Administration: Intravenous

Overview

RQ-2026 is an investigational in vivo chimeric antigen receptor (CAR) T-cell therapy being developed by RNAcure Biotech. The program utilizes mRNA-based technology to engineer T cells directly within the patient's body, bypassing the need for complex and costly ex vivo cell manufacturing. By delivering mRNA encoding a specific CAR, the therapy aims to induce transient CAR expression in endogenous T cells to target and eliminate malignant cells. RQ-2026 is currently in the preclinical stage for the treatment of unspecified cancers, representing a next-generation approach to immunotherapy that seeks to improve patient access and reduce the logistical burdens of traditional cell therapies.

Beyond the preview

Go deeper on RQ-2026.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RQ-2026.

Explore the full profile